At a glance
A single peptide investigated for activity at GIP, GLP-1 and glucagon receptors.
Limits of the evidence. The number of receptor targets is not an effectiveness ranking. Clinical formulation results do not establish equivalence, safety or performance of laboratory material.
Identity and specifications
Retatrutide was originally designated LY3437943. It is a single peptide rather than a mixture of three receptor agonists. Glucagon is not an incretin.
What the selected studies examined
Development work by Coskun and colleagues includes receptor experiments, animal studies and clinical proof-of-concept work. A 2023 phase 2 trial by Jastreboff and colleagues investigated a defined clinical formulation in a controlled population. The study date describes that publication, not the current development phase.
Limitations and open questions
The number of receptor targets is not an effectiveness ranking. Clinical formulation results do not establish equivalence, safety or performance of laboratory material.
These publications describe the materials and experimental conditions used by their authors. They do not establish the identity, composition, stability, safety or performance of East Coast Labs material. A reference list is a selected starting point, not a systematic review.
Interpreting a supplied material
Check the exact product and selected size, then read its documentation status. A historical supplier report describes the named sample at the stated date; it does not establish a match to current stock. Read Testing & quality for the distinction between document authenticity and a documented lot relationship.
Handling, solvent compatibility and stability require material-specific information and a validated laboratory protocol. Published biological findings do not establish storage conditions or suitability for a particular experiment.
